These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Lair-Mehiri L; Stefanescu C; Vaysse T; Laharie D; Roblin X; Rosa I; Treton X; Abitbol V; Amiot A; Bouguen G; Dib N; Fumery M; Pariente B; Carbonnel F; Peyrin-Biroulet L; Simon M; Viennot S; Bouhnik Y Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444 [TBL] [Abstract][Full Text] [Related]
4. Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study. Allocca M; Catalano G; Savarino EV; Chaparro M; Levartovsky A; Michalopoulos G; Viazis N; Fousekis FS; Psistakis A; Noviello D; Nascimento CND; Caron B; Kitsou V; Bamias G; García MJ; Zacharopoulou E; Foteinogiannopoulou K; D'Amico F; Koutroubakis I; Ellul P; Tzouvala M; Peyrin-Biroulet L; Torres J; Caprioli F; Karmiris K; Theodoropoulou A; Katsanos KH; Christodoulou DK; Mantzaris GJ; Kopylov U; Gisbert JP; Danese S; Magro F; Carla F; Fiorino G United European Gastroenterol J; 2024 Jun; 12(5):543-551. PubMed ID: 38419274 [TBL] [Abstract][Full Text] [Related]
5. Tofacitinib Is Associated With Increased Risk of Postoperative Venous Thromboembolism in Patients With Ulcerative Colitis. Russell TA; Banerjee S; Lipman JM; Holubar SD; Hull TL; Steele SR; Lightner AL Dis Colon Rectum; 2024 May; 67(5):693-699. PubMed ID: 38231035 [TBL] [Abstract][Full Text] [Related]
6. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Biemans VBC; Sleutjes JAM; de Vries AC; Bodelier AGL; Dijkstra G; Oldenburg B; Löwenberg M; van Bodegraven AA; van der Meulen-de Jong AE; de Boer NKH; Srivastava N; West RL; Römkens TEH; Horjus Talabur Horje CS; Jansen JM; van der Woude CJ; Hoekstra J; Weersma RK; van Schaik FDM; Hoentjen F; Pierik MJ; Aliment Pharmacol Ther; 2020 May; 51(9):880-888. PubMed ID: 32237087 [TBL] [Abstract][Full Text] [Related]
7. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491 [TBL] [Abstract][Full Text] [Related]
8. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Sandborn WJ; Panés J; Sands BE; Reinisch W; Su C; Lawendy N; Koram N; Fan H; Jones TV; Modesto I; Quirk D; Danese S Aliment Pharmacol Ther; 2019 Nov; 50(10):1068-1076. PubMed ID: 31599001 [TBL] [Abstract][Full Text] [Related]
9. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study. Carvalhas Gabrielli AM; Ferretti F; Monico CM; Tombetti E; Maconi G; Romeo S; Piazza O Sed N; Caprioli F; Mazzola AM; Alicante S; Bertè R; Lolli E; Scribano ML; Buscarini E; Ricci C; Carmagnola S; Ardizzone S; Cannatelli R Dig Dis Sci; 2024 May; 69(5):1785-1792. PubMed ID: 38530500 [TBL] [Abstract][Full Text] [Related]
10. Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis. Adimadhyam S; Lewis JD; Simon AL; Wolfe AE; Smith S; Hou L; Moyneur É; Reynolds JS; Toh S; Dobes A; Parlett L; Haynes K; Burris J; Dorand JE; Long MD; Kappelman MD Inflamm Bowel Dis; 2024 Apr; 30(4):554-562. PubMed ID: 37358904 [TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review. Irving PM; Hur P; Gautam R; Guo X; Vermeire S J Manag Care Spec Pharm; 2024 Sep; 30(9):1026-1040. PubMed ID: 39213145 [TBL] [Abstract][Full Text] [Related]
12. Systematic Review and Meta-Analysis: Preoperative Vedolizumab and Postoperative Complications in Patients with IBD. Moosvi Z; Duong JT; Bechtold ML; Nguyen DL South Med J; 2021 Feb; 114(2):98-105. PubMed ID: 33537791 [TBL] [Abstract][Full Text] [Related]
13. Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study. Kim JY; Zaghiyan K; Lightner A; Fleshner P BMC Surg; 2020 Mar; 20(1):46. PubMed ID: 32138717 [TBL] [Abstract][Full Text] [Related]
14. Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy. Ferrante M; de Buck van Overstraeten A; Schils N; Moens A; Van Assche G; Wolthuis A; Vermeire S; D'Hoore A J Crohns Colitis; 2017 Oct; 11(11):1353-1361. PubMed ID: 28981886 [TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons. Reinisch W; Melmed GY; Nakase H; Seidelin J; Ma C; Xuan S; Tran J; Remple V; Wegrzyn L; Levy G; Sanchez Gonzalez Y; Panaccione R Adv Ther; 2024 Oct; 41(10):3832-3849. PubMed ID: 39126596 [TBL] [Abstract][Full Text] [Related]
16. Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience. Kotwani P; Terdiman J; Lewin S J Crohns Colitis; 2020 Jul; 14(7):1026-1028. PubMed ID: 32020189 [TBL] [Abstract][Full Text] [Related]
17. Factors associated with postoperative morbidity, reoperation and readmission rates after laparoscopic total abdominal colectomy for ulcerative colitis. Gu J; Stocchi L; Remzi F; Kiran RP Colorectal Dis; 2013 Sep; 15(9):1123-9. PubMed ID: 23627886 [TBL] [Abstract][Full Text] [Related]
18. Colectomy is a risk factor for venous thromboembolism in ulcerative colitis. Kaplan GG; Lim A; Seow CH; Moran GW; Ghosh S; Leung Y; Debruyn J; Nguyen GC; Hubbard J; Panaccione R World J Gastroenterol; 2015 Jan; 21(4):1251-60. PubMed ID: 25632199 [TBL] [Abstract][Full Text] [Related]
19. Use of Biological Medications Does Not Increase Postoperative Complications Among Patients With Ulcerative Colitis Undergoing Colectomy: A Retrospective Cohort Analysis of Privately Insured Patients. Rumer KK; Dehghan MS; Sceats LA; Trickey AW; Morris AM; Kin C Dis Colon Rectum; 2020 Nov; 63(11):1524-1533. PubMed ID: 33044293 [TBL] [Abstract][Full Text] [Related]
20. Impact of Biologics and Small-Molecule Agents on Postoperative Complications in IBD: A Systematic Review. Lee KE; Sizemore JA; Kim G; Shen B; Sands BE Dis Colon Rectum; 2024 Jun; 67(S1):S11-S25. PubMed ID: 38294838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]